PHILADELPHIA, PA, UNITED STATES - Jan 12, 2016 - ERT, the leading cloud platform solutions provider delivering clinical and scientific innovation through its patient-centric data collection and intelligence solutions, today announced that for the third consecutive year, over 50% of the compounds approved by U.S. FDA have utilized its cardiac safety, respiratory, and/or electronic Clinical Outcome Assessment (eCOA) solutions to capture critical safety and/or efficacy data during clinical development. The approvals were granted to biopharmaceutical companies from 2013-2015.

Most biopharmaceutical companies partner with solutions providers in order to meet global regulatory agencies’ strict regulations for demonstrating a new compound’s safety and efficacy profile. ERT is a trusted leader in the global clinical trials industry, having supported more than 500 new compounds’ access to market by delivering high quality safety and efficacy endpoint data to sponsors and CROs.

“We are honored that so many biopharmaceutical companies have relied on ERT to support their drug development efforts,” said Jim Corrigan, President and CEO of ERT. “We look forward to strengthening our relationships with these global organizations and to continue providing innovative solutions to help them develop life-saving and life-enhancing medical products for the patients who need them.”

For additional information on ERT’s proven cardiac safety, respiratory, and eCOA solutions and services, visit http://www.ert.com.

About ERT

ERT (http://www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions in centralized Cardiac Safety, Respiratory, Suicide Risk Assessment, electronic Clinical Outcome Assessments (eCOA) - which includes patient-, clinician-, observer- and performance-reported outcomes - and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products.

ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., and in Germany, Japan, Switzerland and the U.K.